Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-Analysis.

Sci Rep · 2015 · PMC4589758 · PMID 26423913

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

a trend toward significanceP = 0.07so close (0.05 < p ≤ 0.1)

None of these adverse outcomes were found to be significantly different between bevacizumab-treated and control groups ( P > 0.05); however, there was a trend toward significance with regard to bevacizumab therapy and the risk of pulmonary embolism ( P = 0.07).

also in 2,517 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.